IMC Immuron

Immuron CEO, Steven Lydeamore, to host an investor webinar

Immuron CEO, Steven Lydeamore, to host an investor webinar

MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.

Wednesday, 7 September 2022 at 9.00am Australian Eastern Standard Time (AEST).



Register in advance for this webinar:







After registering, you will receive a confirmation email containing information about joining the webinar.

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT:



Steven Lydeamore

Chief Executive Officer

Ph: +61 (0)3 9824 5254

  

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN) is a commercial and clinical-stage Australian biopharmaceutical company with a proprietary technology platform focused on a novel class of orally delivered polyclonal antibodies produced from hyperimmune antibody-rich bovine colostrum, for prevention and treatment of gut-mediated diseases.



For more information visit:

 



EN
29/08/2022

Underlying

IMCImmuron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immuron

 PRESS RELEASE
Free
IMC IMMURON

Immuron Travelan® highest sales in history

Immuron Travelan® highest sales in history Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2% on prior yearMarch 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior yearMarch 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter AUD$0.5 million up 28% on prior yearMarch 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE...

April 10, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron’s product portfol...

March 5, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Travelan® continued strong sales growth

Immuron Travelan® continued strong sales growth Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcpDecember 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcpDecember 2024 Half Year AUD$2.9 million up 54% on pcp North America December 2024 Quarter AUD$0.7 million up 43% on prior quarter, up 141% on pcpDecember 2024 Half Year AUD$1.1 million up 130% on pcp MELBOURNE, Australia, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Au...

January 17, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Announces New Research Collaboration targeting Antimicrobial R...

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance Highlights: New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug productsSecond project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) --  Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce a new rese...

January 15, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Announces Travelan® Clinical Trial Update

Immuron Announces Travelan® Clinical Trial Update Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDATravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology ResultsTravelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome ResponsesTravelan® P2TD (n=866) Uniformed Services University field study randomized 776 subjects MELBOURNE, Australia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce th...

January 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch